Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1990 Jul;100(3):651–655. doi: 10.1111/j.1476-5381.1990.tb15862.x

Characterization of cardiac angiotensin converting enzyme (ACE) and in vivo inhibition following oral quinapril to rats.

B Fabris 1, H Yamada 1, R Cubela 1, B Jackson 1, F A Mendelsohn 1, C I Johnston 1
PMCID: PMC1917808  PMID: 2167741

Abstract

1. Angiotensin converting enzyme (ACE) from the rat heart and lung was studied by use of the radioligand [125I]-351A. 2. Displacement of the bound radioinhibitor [125I]-351A was used to assess the relative potency of six ACE inhibitors in rat heart and lung homogenates and estimate the binding association constant (KA). 3. The KA for atrial preparations was significantly higher than that of the lung (P less than 0.025) and also the ventricles (P less than 0.005). Ventricular preparations and preparations from the lung also differed significantly (P less than 0.05). These differences in KA were noted for all six ACE inhibitors used to displace the radioligand. 4. The rank order of potency of the ACE inhibitors was quinaprilat = benazeprilat greater than perindoprilat greater than 351A greater than lisinopril greater than fosinoprilat. 5. Cardiac ACE inhibition was studied ex vivo following oral administration of quinapril to rats. Following 0.3 mg kg-1 quinapril, the time course and degree of inhibition of ventricular and atrial ACE were similar. 6. These results suggest that the detected differences in KA noted have only a limited potential biological significance. The difference in KA may reflect variations in the structure or conformation of ACE in different tissues.

Full text

PDF
651

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Campbell D. J. Circulating and tissue angiotensin systems. J Clin Invest. 1987 Jan;79(1):1–6. doi: 10.1172/JCI112768. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Cleland J. G., Dargie H. J., Ball S. G., Gillen G., Hodsman G. P., Morton J. J., East B. W., Robertson I., Ford I., Robertson J. I. Effects of enalapril in heart failure: a double blind study of effects on exercise performance, renal function, hormones, and metabolic state. Br Heart J. 1985 Sep;54(3):305–312. doi: 10.1136/hrt.54.3.305. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cleland J. G., Dargie H. J., Hodsman G. P., Ball S. G., Robertson J. I., Morton J. J., East B. W., Robertson I., Murray G. D., Gillen G. Captopril in heart failure. A double blind controlled trial. Br Heart J. 1984 Nov;52(5):530–535. doi: 10.1136/hrt.52.5.530. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Daniell H. B., Carson R. R., Ballard K. D., Thomas G. R., Privitera P. J. Effects of captopril on limiting infarct size in conscious dogs. J Cardiovasc Pharmacol. 1984 Nov-Dec;6(6):1043–1047. [PubMed] [Google Scholar]
  5. Dussaule J. C., Michel J. B., Auzan C., Schwartz K., Corvol P., Menard J. Effect of antihypertensive treatment on the left ventricular isomyosin profile in one-clip, two kidney hypertensive rats. J Pharmacol Exp Ther. 1986 Feb;236(2):512–518. [PubMed] [Google Scholar]
  6. Dzau V. J., Colucci W. S., Williams G. H., Curfman G., Meggs L., Hollenberg N. K. Sustained effectiveness of converting-enzyme inhibition in patients with severe congestive heart failure. N Engl J Med. 1980 Jun 19;302(25):1373–1379. doi: 10.1056/NEJM198006193022501. [DOI] [PubMed] [Google Scholar]
  7. Dzau V. J. Implications of local angiotensin production in cardiovascular physiology and pharmacology. Am J Cardiol. 1987 Jan 23;59(2):59A–65A. doi: 10.1016/0002-9149(87)90178-0. [DOI] [PubMed] [Google Scholar]
  8. El-Dorry H. A., Bull H. G., Iwata K., Thornberry N. A., Cordes E. H., Soffer R. L. Molecular and catalytic properties of rabbit testicular dipeptidyl carboxypeptidase. J Biol Chem. 1982 Dec 10;257(23):14128–14133. [PubMed] [Google Scholar]
  9. El-Dorry H. A., Pickett C. B., MacGregor J. S., Soffer R. L. Tissue-specific expression of mRNAs for dipeptidyl carboxypeptidase isoenzymes. Proc Natl Acad Sci U S A. 1982 Jul;79(14):4295–4297. doi: 10.1073/pnas.79.14.4295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Ertl G., Alexander R. W., Kloner R. A. Interactions between coronary occlusion and the renin-angiotensin system in the dog. Basic Res Cardiol. 1983 Sep-Oct;78(5):518–533. doi: 10.1007/BF01906463. [DOI] [PubMed] [Google Scholar]
  11. Fouad F. M., Tarazi R. C., Bravo E. L. Cardiac and haemodynamic effects of enalapril. J Hypertens Suppl. 1983 Oct;1(1):135–142. [PubMed] [Google Scholar]
  12. Fouad F. M., Tarazi R. C., Bravo E. L., Hart N. J., Castle L. W., Salcedo E. E. Long-term control of congestive heart failure with captopril. Am J Cardiol. 1982 Apr 21;49(6):1489–1496. doi: 10.1016/0002-9149(82)90366-6. [DOI] [PubMed] [Google Scholar]
  13. Ganten D., Lang R. E., Lehmann E., Unger T. Brain angiotensin: on the way to becoming a well-studied neuropeptide system. Biochem Pharmacol. 1984 Nov 15;33(22):3523–3528. doi: 10.1016/0006-2952(84)90132-1. [DOI] [PubMed] [Google Scholar]
  14. HUNTER W. M., GREENWOOD F. C. Preparation of iodine-131 labelled human growth hormone of high specific activity. Nature. 1962 May 5;194:495–496. doi: 10.1038/194495a0. [DOI] [PubMed] [Google Scholar]
  15. Hock C. E., Ribeiro L. G., Lefer A. M. Preservation of ischemic myocardium by a new converting enzyme inhibitor, enalaprilic acid, in acute myocardial infarction. Am Heart J. 1985 Feb;109(2):222–228. doi: 10.1016/0002-8703(85)90587-3. [DOI] [PubMed] [Google Scholar]
  16. Iwata K., Lai C. Y., El-Dorry H. A., Soffer R. L. The NH2- and COOH-terminal sequences of the angiotensin-converting enzyme isozymes from rabbit lung and testis. Biochem Biophys Res Commun. 1982 Aug;107(3):1097–1103. doi: 10.1016/0006-291x(82)90634-9. [DOI] [PubMed] [Google Scholar]
  17. Jackson B., Cubela R., Johnston C. I. Measurement of angiotensin converting enzyme inhibitors in serum by radioinhibitor binding displacement assay. Biochem Pharmacol. 1987 Apr 15;36(8):1357–1360. doi: 10.1016/0006-2952(87)90094-3. [DOI] [PubMed] [Google Scholar]
  18. Jackson B., Cubela R., Johnston C. Angiotensin converting enzyme (ACE), characterization by 125I-MK351A binding studies of plasma and tissue ACE during variation of salt status in the rat. J Hypertens. 1986 Dec;4(6):759–765. doi: 10.1097/00004872-198612000-00011. [DOI] [PubMed] [Google Scholar]
  19. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  20. Lindpaintner K., Wilhelm M. J., Jin M., Unger T., Lang R. E., Schoelkens B. A., Ganten D. Tissue renin-angiotensin systems: focus on the heart. J Hypertens Suppl. 1987 Jul;5(2):S33–S38. doi: 10.1097/00004872-198707002-00007. [DOI] [PubMed] [Google Scholar]
  21. Linz W., Schölkens B. A., Han Y. F. Beneficial effects of the converting enzyme inhibitor, ramipril, in ischemic rat hearts. J Cardiovasc Pharmacol. 1986;8 (Suppl 10):S91–S99. doi: 10.1097/00005344-198600101-00017. [DOI] [PubMed] [Google Scholar]
  22. Munson P. J., Rodbard D. Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem. 1980 Sep 1;107(1):220–239. doi: 10.1016/0003-2697(80)90515-1. [DOI] [PubMed] [Google Scholar]
  23. Nakashima A., Angus J. A., Johnston C. I. Comparison of angiotensin converting enzyme inhibitors captopril and MK421-diacid in guinea pig atria. Eur J Pharmacol. 1982 Jul 16;81(3):487–492. doi: 10.1016/0014-2999(82)90114-5. [DOI] [PubMed] [Google Scholar]
  24. Newman T. J., Maskin C. S., Dennick L. G., Meyer J. H., Hallows B. G., Cooper W. H. Effects of captopril on survival in patients with heart failure. Am J Med. 1988 Mar 11;84(3A):140–144. doi: 10.1016/0002-9343(88)90221-5. [DOI] [PubMed] [Google Scholar]
  25. Pfeffer J. M., Pfeffer M. A. Angiotensin converting enzyme inhibition and ventricular remodeling in heart failure. Am J Med. 1988 Mar 11;84(3A):37–44. doi: 10.1016/0002-9343(88)90203-3. [DOI] [PubMed] [Google Scholar]
  26. Pfeffer J. M., Pfeffer M. A., Mirsky I., Braunwald E. Regression of left ventricular hypertrophy and prevention of left ventricular dysfunction by captopril in the spontaneously hypertensive rat. Proc Natl Acad Sci U S A. 1982 May;79(10):3310–3314. doi: 10.1073/pnas.79.10.3310. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Polsky-Cynkin R., Fanburg B. L. Immunochemical comparison of angiotensin 1 converting enzymes from different rat organs. Int J Biochem. 1979;10(8):669–674. doi: 10.1016/0020-711x(79)90210-6. [DOI] [PubMed] [Google Scholar]
  28. Sakharov I. Y., Danilov S. M., Dukhanina E. A. Affinity chromatography and some properties of the angiotensin-converting enzyme from human heart. Biochim Biophys Acta. 1987 Jan 20;923(1):143–149. doi: 10.1016/0304-4165(87)90137-1. [DOI] [PubMed] [Google Scholar]
  29. Sen S., Tarazi R. C., Bumpus F. M. Effect of converting enzyme inhibitor (SQ14,225) on myocardial hypertrophy in spontaneously hypertensive rats. Hypertension. 1980 Mar-Apr;2(2):169–176. doi: 10.1161/01.hyp.2.2.169. [DOI] [PubMed] [Google Scholar]
  30. Sharma J. N., Fernandez P. G., Kim B. K., Idikio H., Triggle C. R. Cardiac regression and blood pressure control in the Dahl rat treated with either enalapril maleate (MK 421, an angiotensin converting enzyme inhibitor) or hydrochlorothiazide. J Hypertens. 1983 Oct;1(3):251–256. doi: 10.1097/00004872-198310000-00009. [DOI] [PubMed] [Google Scholar]
  31. Sharpe N., Murphy J., Smith H., Hannan S. Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction. Lancet. 1988 Feb 6;1(8580):255–259. doi: 10.1016/s0140-6736(88)90347-9. [DOI] [PubMed] [Google Scholar]
  32. Sumners C., Shalit S. L., Kalberg C. J., Raizada M. K. Norepinephrine metabolism in neuronal cultures is increased by angiotensin II. Am J Physiol. 1987 Jun;252(6 Pt 1):C650–C656. doi: 10.1152/ajpcell.1987.252.6.C650. [DOI] [PubMed] [Google Scholar]
  33. Van Gilst W. H., De Graeff P. A., Kingma J. H., Wesseling H., De Langen C. D. Captopril reduces purine loss and reperfusion arrhythmias in the rat heart after coronary artery occlusion. Eur J Pharmacol. 1984 Apr 13;100(1):113–117. doi: 10.1016/0014-2999(84)90323-6. [DOI] [PubMed] [Google Scholar]
  34. Velletri P. A., Billingsley M. L., Lovenberg W. Thermal denaturation of rat pulmonary and testicular angiotensin-converting enzyme isozymes. Effects of chelators and CoCl2. Biochim Biophys Acta. 1985 Mar 29;839(1):71–82. doi: 10.1016/0304-4165(85)90183-7. [DOI] [PubMed] [Google Scholar]
  35. Webster M. W., Fitzpatrick M. A., Nicholls M. G., Ikram H., Wells J. E. Effect of enalapril on ventricular arrhythmias in congestive heart failure. Am J Cardiol. 1985 Sep 15;56(8):566–569. doi: 10.1016/0002-9149(85)91186-5. [DOI] [PubMed] [Google Scholar]
  36. Ziogas J., Story D. F., Rand M. J. Effects of locally generated angiotensin II on noradrenergic transmission in guinea-pig isolated atria. Eur J Pharmacol. 1984 Oct 30;106(1):11–18. doi: 10.1016/0014-2999(84)90672-1. [DOI] [PubMed] [Google Scholar]
  37. de Graeff P. A., van Gilst W. H., Bel K., de Langen C. D., Kingma J. H., Wesseling H. Concentration-dependent protection by captopril against myocardial damage during ischemia and reperfusion in a closed chest pig model. J Cardiovasc Pharmacol. 1987;9 (Suppl 2):S37–S42. doi: 10.1097/00005344-198700002-00009. [DOI] [PubMed] [Google Scholar]
  38. van Gilst W. H., de Graeff P. A., Wesseling H., de Langen C. D. Reduction of reperfusion arrhythmias in the ischemic isolated rat heart by angiotensin converting enzyme inhibitors: a comparison of captopril, enalapril, and HOE 498. J Cardiovasc Pharmacol. 1986 Jul-Aug;8(4):722–728. [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES